Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REASON: Acetyl-L-carnitine to prevent sagopilone-induced peripheral neuropathy
DRKS00003885Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) and ovarian cancer comparing Sagopilone + acetyl-L-carnitine with Sagopilone + placebo (2 arms). Primary endpoints: Incidence and severity of sagopilone-induced peripheral neuropathy and Safety of acetyl-L-carnitine in combination with sagopilone. Started Apr 2012; status: completed.
02
Drugs
acetyl-l-carnitine
03
Conditions
prostate cancer (PCa)ovarian cancer
Beyond the preview
Go deeper on DRKS00003885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003885.